ホーム>>Peptides>>QL9

QL9

カタログ番号GC30580

QL9 (QLSPFPFDL) は、2C T 細胞受容体 (TCR) に対する高親和性同種抗原です。

Products are for research use only. Not for human use. We do not sell to patients.

QL9 化学構造

Cas No.: 159646-83-0

サイズ 価格 在庫数 個数
1mg
$110.00
在庫あり
5mg
$441.00
在庫あり
10mg
$745.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

QL9 (QLSPFPFDL) is a high-affinity alloantigen for the 2C T cell receptor (TCR).

Mouse T cell clone 2C recognizes two different major histocompatibility (MHC) ligands, the self MHC Kb and the allogeneic MHC Ld. Two distinct peptides, SIY (SIYRYYGL) and QL9 (QLSPFPFDL), act as strong and specific agonists when bind to Kb and Ld, respectively. QL9 binding to MHC Ld is influenced by the majority of peptide side chains, distributed across the entire length of the peptide. Findings with both systems, but QL9-Ld in particular, suggest that many single-residue substitutions, introduced into peptides to improve their binding to MHC and thus their vaccine potential, could impair T cell reactivity due to their dual impact on TCR binding. T cell activation assays are performed to measure effects of peptide SIY and QL9 residues on T cell function[2].

[1]. Speir JA, et al. Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes. Immunity. 1998 May;8(5):553-62. [2]. Bowerman NA, et al. Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides. J Biol Chem. 2009 Nov 20;284(47):32551-61.

レビュー

Review for QL9

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for QL9

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.